ClinicalTrials.gg
RecruitingNCT07207941Updated Nov 16, 2026

Effect of Probiotics on Quality of Life, Activities of Daily Living and Anxiety in Post Stroke Patients

An interventional study of Hexbio and Placebo in Stroke, sponsored by National University of Malaysia. Recruiting at 2 sites in Malaysia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by National University of Malaysia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Stroke with a site in Malaysia — 6 open to participants now, 8 under way, 2 of them phase 3. Stroke · Malaysia.

Planned enrollment
27th of 40
110 · median 345
Started
2026
with 2 others
No phase
18 of 45
4 open now
Registered
39th of 45
by date

Among the 45 studies in Stroke with a site in Malaysia, this one is the 27th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, and was the 39th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 45 studies in Stroke with a site in Malaysia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Stroke with a site in Malaysia, or all of them as a file.
02

Study summary

Research on Effect of probiotics on quality of life, activities of daily living and anxiety in post stroke patients

Read the detailed description

Background:

Stroke survivors often experience reduced quality of life (QoL), impaired activities of daily living (ADL), and high levels of anxiety. Emerging evidence suggests that modulation of the gut-brain axis through probiotics may improve neuropsychological and functional outcomes. However, data from Malaysian populations are lacking.

Objective:

To evaluate the effects of probiotic supplementation compared to placebo on QoL, ADL, anxiety symptoms, and functional outcomes in post-stroke patients.

Study Design:

This is a single-center, randomized, double-blind, placebo-controlled clinical trial.

Methods:

A total of 110 patients with moderate ischemic stroke (mRS 2-4) within 3 months of onset will be recruited from the Neurology Clinic, Hospital Canselor Tuanku Muhriz, Kuala Lumpur. Participants will be randomized (1:1) to receive either:

  • Intervention: HEXBIO MCP Granule probiotics (Lactobacillus acidophilus, L. casei, L. lactis, Bifidobacterium bifidum, B. infantis, B. longum), one sachet twice daily for 3 months.
  • Control: Matching placebo sachets, identical in appearance and schedule. Both groups will continue standard stroke treatment. Primary outcome is QoL measured using the Stroke-Specific Quality of Life (SS-QoL) scale. Secondary outcomes include ADL (Barthel Index), anxiety symptoms (GAD-7), and functional status (mRS score). Assessments will be performed at baseline and 3 months.

Sample Size:

A total of 110 patients (55 per arm) will provide sufficient power to detect clinically meaningful differences, accounting for a 5% dropout rate.

Data Analysis:

Intention-to-treat analysis will be conducted using SPSS v26. Between-group differences will be assessed using appropriate parametric or non-parametric tests, with significance set at p \< 0.05.

Study Duration:

Recruitment will begin in Sept 2025 and is expected to complete by May 2028.

Expected Impact:

This study will provide new evidence on the role of probiotics in improving QoL, daily functioning, and psychological well-being among Malaysian post-stroke patients, potentially informing adjunctive rehabilitation strategies.

03

Conditions studied

  • Stroke

Keywords

  • stroke
  • probiotic
  • quality of life
  • anxiety
  • activities of daily living
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with moderate ischemic stroke with mRS score of 0-4 from onset of stroke.
  • Patients aged 18 to 80 years, who are able to read and write in English and/or Bahasa Malaysia
  • Provide

Exclusion criteria

Exclusion Criteria:

  • Patients with aphasia
  • Patients who have received thrombolysis or mechanical thrombectomy
  • Gastrointestinal related diseases such as lactose intolerance, coeliac disease, Renal or hepatic insufficiency (Based on recent six-month blood profile)
  • Progressive neurological disease (Alzheimer's disease, Parkinson's Disease, Motor Neuron Disease)
  • Pregnancy and breastfeeding.
  • Secondary cause of stroke- vasculitis, cerebral venous sinus thrombosis, connective tissue disorders
  • Past history of psychiatric disorders (depression, anxiety)
  • Recent use of probiotics and allergies to probiotics
  • patients (, )
  • Patient with septicemia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Intervention

    Intervention group HEXBIO MCP Granule probiotics (Lactobacillus acidophilus, L. casei, L. lactis, Bifidobacterium bifidum, B. infantis, B. longum), one sachet twice daily for 3 months.

    Dietary Supplement: Hexbio

  • Placebo comparator
    Placebo

    Placebo Control Matching placebo sachets, identical in appearance and schedule.

    Other: Placebo

Interventions

  • Dietary supplementHexbio

    HEXBIO MCP Granule probiotics (Lactobacillus acidophilus, L. casei, L. lactis, Bifidobacterium bifidum, B. infantis, B. longum), one sachet twice daily for 3 months.

  • OtherPlacebo

    Matching placebo sachets, identical in appearance and schedule

06

What researchers measure

Primary outcomes

  1. Primary Objective

    QoL measured using the Stroke-Specific Quality of Life (SS-QoL) scale. To assess the patient's quality of life, validated Stroke Specific Quality of life (SS-QoL) questionnaire in English version will be used. This questionnaire consists of 12 domains which includes energy, family roles, language, mobility, mood, personality, self-care, social roles, thinking, upper extremity function, vision, and work/productivity. Each question is scored using 5 point Likert scale and the total score is calculated which can range from 49-245. The higher the score, better the quality of life. This questionnaire is validated and requested for permission.

    Time frame: 3 months

Secondary outcomes

  1. Secondary objectives: Activities of daily living

    Activities of daily living is measured using Barthel Index (BI) which contains of 10 items. BI is a measurement scale used to assess an individual's ability to perform activities of daily living (ADL) and mobility. The score ranges from 0-10 and the overall score is calculated. The higher the score, better the functional status.

    Time frame: 3 months

  2. Secondary objective: Anxiety Score

    Anxiety score is calculated using Generalised Anxiety Disorder- 7 (GAD-7) score. GAD 7 is a screening tool and it has 7 items with score ranging from 0-3 for each item and the total score is calculated. The higher the score, the worse the anxiety symptoms. A score of 10 indicates anxiety.

    Time frame: 3 months

  3. Secondary objective: modified Rankin scale

    Modified Rankin Scale (mRS) assess functional recovery and independence after stroke. It uses a 5 point scale, where a higher scale indicates more severe disability.

    Time frame: 3 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Study has not commenced

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 23 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Sep 2025 → Jan 2026 and primary completion Sep 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 6, 2025
StartActual
Jan 1, 2026was Sep 2025
Primary completionEst.
Dec 31, 2027was Sep 2025
CompletionEst.
May 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
1 site added. National University of Malaysia is now Recruiting
Show site
  • Hospital Canselor Tuanku Muhriz · Kuala Lumpur, Malaysia
Nov 16, 2026
Start date
Sep 30, 2025→Jan 1, 2026 (actual)
Nov 16, 2026
Primary completion
Sep 30, 2025→Dec 31, 2027
Nov 16, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatients diagnosed with moderate ischemic stroke with mRS score of 20-4 from onset of stroke up to 3 months.
Nov 16, 2026
Sponsor
Collaborators added: B-Crobes Laboratory; collaborators removed: B-Crobes Laboratory Sdn. Bhd
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    1 site added. National University of Malaysia is now Recruiting
    Show site
    • Hospital Canselor Tuanku Muhriz · Kuala Lumpur, Malaysia
    Start date Sep 30, 2025→Jan 1, 2026 (now actual)
    Primary completion Sep 30, 2025→Dec 31, 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients diagnosed with moderate ischemic stroke with mRS score of 20-4 from onset of stroke up to 3 months.
    Sponsor Collaborators added: B-Crobes Laboratory; collaborators removed: B-Crobes Laboratory Sdn. Bhd
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07207941
Collaborators
B-Crobes Laboratory
Responsible party
Tan Hui Jan (Consultant Neurologist, National University of Malaysia) — Principal investigator
First posted
Oct 6, 2025
Start date
Jan 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Hui Jan Tan, MD FRCP MMed
Contact
tanhuijan@ukm.edu.my
+60391455555 ext. 5583
Nasir Shafiee
study director · National University of Malaysia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion